$AARD News

HC Wainwright & Co. Maintains Neutral on Aardvark Therapeutics, Lowers Price Target to $2

Aardvark Therapeutics, Inc. (AARD) Discusses Efficacy and Safety Data From Terminated HERO Phase III and Open-Label Extension Trials Transcript

Aardvark Therapeutics Says Current Prader-Willi Syndrome Drug Data Insufficient

Aardvark Therapeutics Reports Exploratory Data from the Terminated HERO and Open-Label Extension Trials

Aardvark Therapeutics Reports Exploratory Phase 3 HERO And OLE Data Showing Rapid Hunger Score Reductions With ARD-101 In PWS, FDA Lifts Clinical Hold And Company Targets New Phase 3 Trial

Aardvark Therapeutics Stock Surges as FDA Lifts Clinical Hold After Cardiac Safety Concerns

Aardvark Therapeutics stock surges as FDA lifts clinical hold

Aardvark Therapeutics Announces FDA Has Lifted the Clinical Hold on ARD-101 for the Treatment of Prader-Willi Syndrome and Will Host Webcast to Review the Available Exploratory Phase 3 HERO/OLE Data

FDA Removes Clinical Hold From Aardvark Therapeutics' Investigational New Drug Application For ARD-101 To Treat Hyperphagia In Prader-Willi Syndrome

All You Need to Know About Aardvark Therapeutics, Inc. (AARD) Rating Upgrade to Buy

HC Wainwright & Co. Maintains Neutral on Aardvark Therapeutics, Lowers Price Target to $4

Aardvark Therapeutics Appoints Clinical Development Leader David Zhang, Ph.D., MBA, to its Board of Directors

Aardvark Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

RBC Capital Reiterates Sector Perform on Aardvark Therapeutics, Maintains $6 Price Target

Aardvark Therapeutics Inc (AARD) (Q2 2026) Earnings Call Highlights: Board Re-Elected, Auditor ...

Aardvark Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates

Aardvark Therapeutics Q2 EPS $(0.66) Beats $(0.91) Estimate

HC Wainwright & Co. Reiterates Neutral on Aardvark Therapeutics, Announces $6 Price Target

Several Insiders Invested In Aardvark Therapeutics Flagging Positive News

Aardvark Therapeutics: Regulatory Uncertainty Clouds ARD-101 Path Forward